Compare HWH & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWH | ACXP |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.3M |
| IPO Year | 2022 | 2021 |
| Metric | HWH | ACXP |
|---|---|---|
| Price | $1.68 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | ★ 743.1K | 79.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $866,926.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.29 |
| 52 Week High | $7.77 | $8.34 |
| Indicator | HWH | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 75.77 | 34.12 |
| Support Level | $1.00 | $1.37 |
| Resistance Level | $1.85 | $2.26 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 42.50 | 10.89 |
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.